CA-YOKOGAWA-ELECTRIC
25.3.2022 06:02:12 CET | Business Wire | Press release
Yokogawa Electric Corporation (TOKYO: 6841) announces that it has successfully completed a proof of concept test of technology that reduces energy consumption and stabilizes the quality of the water discharged by the Tapia Water Reclamation Facility of the Las Virgenes Municipal Water District (LVMWD), located in Los Angeles County, California. This initiative was undertaken as part of the company’s proposal to improve the performance of existing wastewater reclamation facilities in conjunction with a program sponsored by the Japan Ministry of Economy, Trade and Industry that seeks to examine opportunities for the overseas deployment of high quality energy infrastructure.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220324006055/en/
Water stress is an increasingly pressing issue worldwide due to the effects of climate change and the rising demand for water driven by population growth. In order to ensure stability in water resources, more and more countries are looking to make proactive use of reclaimed water. In the USA, the state of California is considering changes in regulations*1 that will allow the direct use of reclaimed water for drinking water by the end of 2023, and this is the subject of serious discussions and cooperation between the public and private sectors.
This proof of concept was conducted as part of the Pure Water Project and led by the LVMWD, whose aim is to produce potable water from highly treated wastewater in compliance with State water quality standards. Doing so required LVMWD to consider alternative technological approaches, as treating water to potable quality consumes enormous amounts of electricity and is more maintenance intensive. Yokogawa has been studying ways to address such challenges by making use of the company’s extensive process knowledge and experience in monitoring and control of industrial facilities.
Given the large fluctuations in the quality of the wastewater that flows into reclamation facilities, plant operators must take proper care while monitoring the inflow rate to ensure that the mandated water quality standards are met, and rely on their knowledge and technical expertise to make the necessary adjustments. Yokogawa applied its advanced data driven modeling for optimization (DDMO) software suite to model and then predict setpoints to optimize operations and support operator decision making while maintaining the targeted water quality at water treatment facilities.
As this proof of concept was conducted during the COVID-19 pandemic, Yokogawa used its Yokogawa Cloud platform to minimize the site activities and move site data to Japan where the DDMO software utilized real-time operational data to derive control setpoints that were sent back to operators at the Tapia Water Reclamation Facility. After conducting a multifaceted evaluation and performing a concrete verification of effectiveness, it was revealed that improvements in operational efficiency had yielded an over 10% reduction in power consumption, while meeting all water quality standards. Impressed with these results, the WateReuse Association presented Yokogawa and its partners with a 2022 Transformational Innovation award*2 .
Tsuyoshi Abe, a Yokogawa Electric vice president and head of the Marketing Headquarters, says, “Water is a public asset and a finite resource. Goal 6 of the SDGs is to ‘Ensure access to water and sanitation for all,’ and this is an important area where Yokogawa can contribute. Toward this end, the effective utilization of reclaimed water as a sustainable water source for communities is a groundbreaking approach. The efficient purification and provision of safe and secure drinking water requires the understanding of all stakeholders and a lot of revolutionary technology. In order to build a circular ecosystem for water resources and create new value, we will work to further strengthen our collaboration with partners to drive forward co-innovation, and utilizing our capabilities to measure and connect, we will fulfill our responsibilities for the future of our planet.”
*1 The California Water Boards: Regulating direct potable reuse in California
https://www.waterboards.ca.gov/drinking_water/certlic/drinkingwater/direct_potable_reuse.html
*2 WateReuse Awards for Excellence, Transformational Innovation award, presented at the 37th Annual WateReuse Symposium. Award recipients: Yokogawa Electric Corporation, Las Virgenes Municipal Water District, Carollo Engineers, the National Water Research Institute, Metropolitan Water District, Bureau of Reclamation, IOSight
https://watereuse.org/news-events/awards/past-award-winners/watereuse-award-winners-2022/
About Yokogawa
Yokogawa provides advanced solutions in the areas of measurement, control, and information to customers across a broad range of industries, including energy, chemicals, materials, pharmaceuticals, and food. Yokogawa addresses customer issues regarding the optimization of production, assets, and the supply chain with the effective application of digital technologies, enabling the transition to autonomous operations.
Founded in Tokyo in 1915, Yokogawa continues to work toward a sustainable society through its 17,500 employees in a global network of 119 companies spanning 61 countries.
For more information, visit www.yokogawa.com
The names of corporations, organizations, products, services and logos herein are either registered trademarks or trademarks of Yokogawa Electric Corporation or their respective holders.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220324006055/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
